Twist Bioscience to Announce Q1 Earnings on February 2nd
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6h ago
0mins
Source: seekingalpha
- Earnings Announcement: Twist Bioscience is set to release its Q1 earnings on February 2nd before market open, with consensus EPS estimate at -$0.52 and revenue forecast at $102.04 million, reflecting a 15% year-over-year growth.
- Performance Track Record: Over the past year, Twist has beaten EPS estimates 75% of the time and has successfully exceeded revenue estimates 100% of the time, indicating a strong performance consistency.
- Long-Term Growth Target: The company aims for a revenue growth target of 13% to 15.5% by 2026, driven by accelerating AI-driven orders, highlighting its strategic focus on technological innovation.
- Recent Financial Results: In its latest report, Twist Bioscience posted a GAAP EPS of -$0.45, missing estimates by $0.03, while revenue reached $99 million, surpassing expectations by $1.64 million, showcasing its revenue growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TWST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TWST
Wall Street analysts forecast TWST stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TWST is 41.25 USD with a low forecast of 39.00 USD and a high forecast of 43.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 41.580
Low
39.00
Averages
41.25
High
43.00
Current: 41.580
Low
39.00
Averages
41.25
High
43.00
About TWST
Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. It has applied its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next generation sequencing (NGS) sample preparation, and antibody libraries for drug discovery and development, all designed to enable its customers to conduct research. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. The Company's synthetic DNA tools are used in fields, such as medicine, agriculture, industrial chemicals and defense. It has minority ownership in Atlas Data Storage, Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Twist Bioscience to Announce Q1 Earnings on February 2nd
- Earnings Announcement: Twist Bioscience is set to release its Q1 earnings on February 2nd before market open, with consensus EPS estimate at -$0.52 and revenue forecast at $102.04 million, reflecting a 15% year-over-year growth.
- Performance Track Record: Over the past year, Twist has beaten EPS estimates 75% of the time and has successfully exceeded revenue estimates 100% of the time, indicating a strong performance consistency.
- Long-Term Growth Target: The company aims for a revenue growth target of 13% to 15.5% by 2026, driven by accelerating AI-driven orders, highlighting its strategic focus on technological innovation.
- Recent Financial Results: In its latest report, Twist Bioscience posted a GAAP EPS of -$0.45, missing estimates by $0.03, while revenue reached $99 million, surpassing expectations by $1.64 million, showcasing its revenue growth potential.
Continue Reading
Planet Labs PBC Secures Nine-Figure Deal with Swedish Armed Forces, Shares Surge 7%
- Stock Surge: Planet Labs PBC's announcement of a multi-year nine-figure agreement with the Swedish Armed Forces led to a 7% increase in share price to $24.29 on Monday, reflecting strong market confidence in the company's long-term contracts.
- Revenue Outlook Boost: Day One Biopharmaceuticals Inc reported preliminary 2025 OJEMDA net product revenue of $155.4 million, up 172% year-over-year, indicating robust growth potential in the biopharmaceutical sector that may attract more investor interest.
- Market Dynamics: Amid a broader decline in U.S. stocks, Wheels Up Experience Inc saw its shares jump 30.2% to $0.89, suggesting a market reassessment of its business model, potentially providing support for future financing and expansion.
- Increased Demand for Safe Assets: Growing concerns about Federal Reserve independence have led investors to shift towards safe-haven assets like gold, driving up precious metals stocks, which reflects market sensitivity to economic uncertainties and a preference for secure investments.
Continue Reading